Literature DB >> 16465410

Alterations in novel candidate tumor suppressor genes, ING1 and ING2 in human lung cancer.

Tetsuya Okano1, Akihiko Gemma, Yoko Hosoya, Yukio Hosomi, Michiya Nara, Yutaka Kokubo, Akinobu Yoshimura, Masahiko Shibuya, Makoto Nagashima, Curtis C Harris, Shoji Kudoh.   

Abstract

The ING1 gene is involved in the regulation of the cell cycle, senescence, and apoptosis and is a novel candidate tumor suppressor gene. ING2, another gene in the ING family, was identified and cloned. The functions of ING1 and ING2 largely depend on the activity of p53. To determine whether an alteration in these genes plays a role in carcinogenesis and tumor progression in lung cancer, we screened 30 human lung cancer cell lines and 31 primary lung cancer tumors for mutations in these genes using polymerase chain reaction-single strand conformation polymorphism (PCR-SSCP) and direct sequencing. Our findings failed to uncover any mutations in these genes. We also examined the expression of ING1 and ING2 in lung cancer cell lines that either had or lacked a p53 mutation, and in a control bronchial epithelium cell line, using quantitative real-time reverse transcription-polymerase chain reaction (RT-PCR). ING1 expression was up-regulated in all 7 lung cancer cell lines that had a p53 mutation, while the expression of ING2 was down-regulated in 6 of 7 lung cancer cell lines that had a p53 mutation. These results suggest that the ING1 and ING2 genes have different roles in lung carcinogenesis and progression, and the ING2 gene may be an independent tumor suppressor candidate on p53.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16465410

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  17 in total

1.  Frequent deletion of ING2 locus at 4q35.1 associates with advanced tumor stage in head and neck squamous cell carcinoma.

Authors:  Silvia S Borkosky; Mehmet Gunduz; Hitoshi Nagatsuka; Levent Bekir Beder; Esra Gunduz; Mahmoud A L Sheikh Ali; Andrea P Rodriguez; Mehmet Zeynel Cilek; Susumu Tominaga; Noboru Yamanaka; Kenji Shimizu; Noriyuki Nagai
Journal:  J Cancer Res Clin Oncol       Date:  2008-11-08       Impact factor: 4.553

Review 2.  Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials.

Authors:  Yuan Cheng; Cai He; Manni Wang; Xuelei Ma; Fei Mo; Shengyong Yang; Junhong Han; Xiawei Wei
Journal:  Signal Transduct Target Ther       Date:  2019-12-17

3.  Downregulation of inhibitor of growth 3 is correlated with tumorigenesis and progression of hepatocellular carcinoma.

Authors:  Meiling Lu; Fei Chen; Qinwan Wang; Kesheng Wang; Qiuhui Pan; Xin Zhang
Journal:  Oncol Lett       Date:  2012-04-19       Impact factor: 2.967

Review 4.  Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials.

Authors:  Yuan Cheng; Cai He; Manni Wang; Xuelei Ma; Fei Mo; Shengyong Yang; Junhong Han; Xiawei Wei
Journal:  Signal Transduct Target Ther       Date:  2019-12-17

Review 5.  ING1 and ING2: multifaceted tumor suppressor genes.

Authors:  Claire Guérillon; Delphine Larrieu; Rémy Pedeux
Journal:  Cell Mol Life Sci       Date:  2013-02-15       Impact factor: 9.261

Review 6.  Inhibitor of growth tumor suppressors in cancer progression.

Authors:  Brad Piche; Gang Li
Journal:  Cell Mol Life Sci       Date:  2010-03-02       Impact factor: 9.261

7.  A novel tumor suppressor gene in basal cell carcinoma: inhibition of growth factor-2.

Authors:  Metin Temel; Arif Turkmen; Recep Dokuyucu; Cengiz Cevik; Serdar Oztuzcu; Beyhan Cengiz; Mehmet Mutaf
Journal:  Tumour Biol       Date:  2015-01-23

Review 8.  ING proteins as potential anticancer drug targets.

Authors:  M Unoki; K Kumamoto; C C Harris
Journal:  Curr Drug Targets       Date:  2009-05       Impact factor: 3.465

Review 9.  The ING gene family in the regulation of cell growth and tumorigenesis.

Authors:  Andrew H Coles; Stephen N Jones
Journal:  J Cell Physiol       Date:  2009-01       Impact factor: 6.384

Review 10.  Reviewing the current classification of inhibitor of growth family proteins.

Authors:  Motoko Unoki; Kensuke Kumamoto; Seiichi Takenoshita; Curtis C Harris
Journal:  Cancer Sci       Date:  2009-04-28       Impact factor: 6.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.